Lupin has launched Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation. Ganirelix Acetate Injection had estimated annual sales of $87 million in the U.S. (IQVIA MAT December 2023).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
